Eliem Therapeutics Files 8-K for Security Holder Votes and Other Events

TL;DR

Eliem Therapeutics filed an 8-K for shareholder votes and other events. Details TBD.

AI Summary

Eliem Therapeutics, Inc. filed an 8-K on June 26, 2024, to report on matters submitted to a vote of its security holders and other events. The filing does not contain specific details about the votes or events, but it serves as a notification to the SEC.

Why It Matters

This filing indicates that Eliem Therapeutics has held or will hold votes involving its security holders and has other corporate events to report, which could impact company governance and operations.

Risk Assessment

Risk Level: low — The filing is a standard procedural notification and does not disclose any immediate financial or operational risks.

Key Players & Entities

• Eliem Therapeutics, Inc. (company) — Registrant
• June 26, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 1-877-ELIEMTX (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ELYM The Nasdaq Stock Mar

Filing Documents

• d788381d8k.htm (8-K) — 43KB
• 0001193125-24-169077.txt ( ) — 166KB
• elym-20240626.xsd (EX-101.SCH) — 3KB
• elym-20240626_lab.xml (EX-101.LAB) — 18KB
• elym-20240626_pre.xml (EX-101.PRE) — 11KB
• d788381d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: completion of the proposed acquisition and concurrent financing and the transactions contemplated by the Acquisition Agreement and the Securities Purchase Agreement. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with completion of the proposed acquisition and concurrent financing in a timely manner or on the anticipated terms or at all; the satisfaction (or waiver) of closing conditions to the consummation of the acquisition and concurrent financing; risks related to the Company's and Tenet's ability to estimate their respective operating expenses and expenses associated with the transaction; uncertainties regarding the impact any delay in the closing would have on the anticipated cash and cash equivalents of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash and cash equivalents; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Acquisition Agreement; the effect of the announcement or pendency of the acquisition on the Company's or Tenet's business relationships, operating results and business generally; the ability of the combined company to timely and successfully achieve or recognize the anticipated benefits of the acquisition; the outcome of any legal proceedings that may be instituted against the Company or Tenet following the announcement of th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eliem Therapeutics, Inc. Date: June 26, 2024 By: /s/ Andrew Levin Andrew Levin, M.D., Ph.D. Executive Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR